Constitutive over-expression of IDO has been observed in AML blast cells and patient sera [522,523,526], correlates with increased levels of circulating Tregs in patients with AML at initial diagnosis [524], and has been linked with poor clinical outcome (decreased relapse-free and overall survival) in patients with AML [527]. This evidence concerns the gene IDO1 and acute myeloid leukemia.